Pedro de Noronha Pissarra

Are you a manufacturer of Digital Therapeutics (DTx) with a focus on the UK market? In this blog post, we delve into the intricacies of Digital Therapeutics (DTx) regulation in the UK, especially in light of Brexit in January 2020. 👉 https://lnkd.in/eqYb38ZF #DTx #DigitalTherapeutics #RegulatoryAffairs #Brexit

11

Looking forward to attending the LSX Investival Showcase in London next week to meet up with familiar faces as well as making new connections. Please do get in touch if you’d like to meet there to discuss the latest developments for maraciclatide, including the latest findings from our DETECT endometriosis Phase II study and the start of our Phase III trials in inflammatory arthritis. #endometriosis #womenshealth #inflammatoryarthritis #molecularimaging #diagnosticimaging #medicalimaging #precisionmedicine #nuclearmedicine

8

Rapid, detailed cell analysis technology soon ready to assess the difference it can make to process insights and timelines

11

Dr Jen Vanderhoven is bar far one of the most passionate and driven people I know. I honestly believe she is single handedly making the most Impact for #ukbiotech and #bio-based materials. Making the BBIA the fastest growing most modern trade association trying to make a #realdifference. If you want to be apart of the #bioeconomy and #biorevolution get in touch. Keir Starmer

10

1 Comment

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

2

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

2

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

3

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

3